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ABSTRACT
The Role of Non-Neuronal Acetylcholine in Urogenital Chlamydial Infection
by
Jessica Lockhart

Chlamydia trachomatis causes a bacterial sexually transmitted infection, Chlamydia, that is often
chronic and causes reproductive complications in women. We hypothesized that Chlamydia
infection increases local acetylcholine (ACh) production, which regulates the host’s
inflammatory response to the infection. Female mice infected with C. muridarum were sacrificed
at days 3, 9, 15, and 21 post-infection, genital tract tissues harvested, and immunohistochemistry
performed to enumerate ACh-producing cells. Infection increased the number of ACh-producing
cells in cervical tissue at days 3, 15 and 21 post-infection (pi), uterine tissue at days 3 and 9 pi,
and ovarian tissue at days 3, 15 and 21 pi. These findings suggest that C. trachomatis increases
ACh production, which may suppress host’s immunity and aid in establishing chronic infection.
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CHAPTER 1
INTRODUCTION
Chlamydia trachomatis is the organism responsible for the most prevalent bacterial
sexually transmitted infection in the United States, known as Chlamydia or chlamydial infection.
In 2016, there were approximately 1.6 million cases reported to the Centers for Disease Control
and Prevention (CDC) and an estimated 2.86 million new cases of infection in the US alone.1
The large discrepancy in reported cases and estimated new cases of chlamydial infection can be
attributed to the often-asymptomatic nature of the infection.2 While chlamydial infection may be
asymptomatic, it can still cause inflammation and tissue damage, which may result in potentially
life-altering complications. Chlamydial infection is not restricted to the United States; in 2012,
there were an estimated 131 million new chlamydial infections worldwide,3, 4 indicative of a
global problem.
The genus Chlamydia is part of the family Chlamydiaceae, of the order Chlamydiales, of
the phylum Chlamydiae, belonging to the Bacteria kingdom.5 All species in the Chlamydia genus
are Gram-negative obligate intracellular bacteria. Within the unique species Chlamydia
trachomatis, there are multiple serovars. The serovars A, B, Ba, and C are most commonly
associated with trachoma, an infection affecting the eyes that is the most common infectious
cause of blindness worldwide.6 The serovars D through K are those typically associated with
non-invasive genital tract infections.7, 8.
Non-invasive urogenital chlamydial infection is associated with a number of
complications and sequelae. However, one of the confounding factors with identifying infected
individuals and initiating treatment corresponds with the findings of a 2003 study. This study
found that, of those with urogenital chlamydial infection, only about 10% of men and 30% of
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women show symptoms.9 As a result, individuals without symptoms who have current infections
due to the C. trachomatis bacteria are at risk of spreading the disease unknowingly. In addition,
they are also at increased risk of HIV acquisition if they have sexual contact with individuals
who are HIV infected.10 In addition, there are a number of possible symptoms and complications
of chlamydial infection related to the inflammatory processes. Chlamydial infection-associated
inflammation can result in urethritis in both males and females and proctitis in males. It can also
result in cervicitis and pelvic inflammatory disease (PID) in females. Long-term effects of PID
may include tubo-ovarian abscess, tubal factor infertility, ectopic pregnancy, and chronic pelvic
pain. Antibiotics can eliminate infection and cure PID; however, they cannot alter lasting
damage that may have occurred as a result of the infection, such as genital tract scarring that
results in infertility.

Significance of the Issue
Sexually active females between the ages of fifteen and twenty-four years of age have the
highest rate of chlamydial infection, with an estimated rate of 1 in every 20 women in this age
range is infected with Chlamydia trachomatis in the United States.1 A study published in 2011
found that seven years after a clinical PID diagnosis, 21.3% of women in the study had recurring
PID, 19.0% had developed infertility, and 42.7% of women reported having chronic pelvic
pain.11 In addition, women that experience recurrent PID are 1.8 times more likely to have
trouble conceiving in a twelve month period with little or no contraception use.12 This means that
many young women, who are infected with Chlamydia but do not receive appropriate and timely
medical care, may be at risk of developing PID, which can greatly impact their reproductive
futures.

10

The Arrested Immunity Hypothesis
In chlamydial biology, the arrested immunity hypothesis has been proposed to explain
persistent or recurrent chlamydial infections. The hypothesis states that, while treatment can halt
progression of genital tract infection and subsequent disease, early treatment may eliminate the
organism but can also reduce development of Chlamydia-specific adaptive immune responses.
Thus, individuals who are infected and then treated may not develop sufficient anti-chlamydial T
cell responses and the antibodies necessary to resist re-infection. Stimulation of innate immune
responses, which would be expected to occur before treatment, is likely insufficient to protect
against re-infection.13 Ultimately, if these individuals are re-exposed, they will not have
sufficient pre-existing immunity to protect them from re-infection. Unless lifestyle changes are
made in regard to sexual activity, previously infected individuals who receive treatment but do
not develop the necessary adaptive immune response to combat the infection are likely to acquire
the infection again from an infected sexual partner. In addition, if the first or a subsequent
infection remains asymptomatic and is not treated, this could lead to chronic infection and
increased risk of future adverse reproductive consequences.

Chlamydial Genomics
Stephens et al. published the first genome sequence report for a human urogenital
pathogenic chlamydial strain in 1998. This genome sequence and subsequent analysis for C.
trachomatis serovar D has been one of the most productive advancements in the field of
Chlamydia research. Chlamydiae are known to have genome sequences that are comparatively
smaller than many other bacteria. C. trachomatis has a 1.04Mb genome sequence,14, 15 which is
approximately half the size of the average extracellular urogenital bacteria, at 2.11Mb,16 and they
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have limited abilities when it comes to performing many metabolic functions. It has been
suggested that the relatively small genome of the species within the genus Chlamydia is related
to their obligate intracellular parasitic relationship with their hosts.7, 8, 14 C. muridarum, which is
an oft-used organism for modeling infection with C. trachomatis, has largely conserved and
highly similar genomes and biosynthetic functions.17

Chlamydial Developmental Cycle
C. trachomatis is a Gram-negative, obligate intracellular bacterium. It has a unique
developmental cycle (Figure 1), existing in one of two forms. In the smaller, elementary body
(EB) form, the Chlamydiae are infectious and capable of entering the host. EB use small
endosome-like vacuoles to enter the host epithelial cells. The EB form of C. trachomatis, similar
to other bacterial pathogens, can alter the host’s functions and signaling pathways to make the
environment conducive to survival, which helps prevent endosome acidification. This allows the
Chlamydiae to avoid being killed by the host’s lysosome contents.18 Once the EB form enters the
host cell through receptor-mediated endocytosis, 19 it can form a membrane-bound protective
environment, called an inclusion. In order for chlamydial cells to reproduce, they must convert
into the reticulate body (RB) form.7 The reticulate body form is the non-infectious, intracellular
form in which the chlamydiae divide and benefit from the host’s natural resources and processes.
Thus, the RB is the replicative form of the organism, and the reticulate bodies divide by binary
fission. Once the reticulate body cells have successfully reproduced, they are then able to
reorganize into the elementary body form once again. The elementary body cells are released
from the host cell and are now able to go out and infect other cells.20, 21
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Figure 1. The Chlamydial Developmental Cycle. The host cells are infected by the elementary
body (EB) form. The elementary bodies enter the host cells and are converted to reticulate bodies
(RB). In the RB form, they are more metabolically active and undergo multiplication. The
inclusions also increase in size. In the presence of stressors such as β-Lactam antibiotics, lack of
necessary nutrients, and heat shock, the RB can convert into aberrant bodies (AB), which may
aid in the persistence of chlamydial cells in the host. In the absence of these stressors, the AB can
return to the RB form. RB convert to the EB form, and they exit the cell through extrusion or
lysis. In the case of extrusion, the inclusion can rupture, which releases EB and allows the EB to
infect other cells.
Further study of the developmental cycle and persistence of chlamydial infection
indicates that there is an additional form, the aberrant body (AB; Figure 1). Reports of a
chlamydial body that fits neither the RB nor the EB form date back to at least 1950, when Weiss
noticed that Chlamydia psittaci transitioned into a new developmental form when exposed to
certain stressors.22 Examples of stressors that can induce transition into this new form include
environments that do not provide the necessary nutrients, as well as exposure to β-Lactam
antibiotics.23 After induction into these AB, the chlamydial cells can persist until these stressors
are no longer present, as long as they have a healthy host cell. Once the stressor is removed, the
AB revert back into RB, which continue to develop into infectious EB as described above.
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Conversion to these aberrant bodies gives the infectious cells a method to escape conditions that
might otherwise result in death of the chlamydial cells. It should be noted that review of
published work by Bavoil cautions against using terminology such as aberrant bodies or
persistent bodies, as it implies that these abnormal chlamydiae are universal in features.24 There
are a number of characteristics and details about aberrant bodies that are yet to be discovered and
understood, including whether the aberrant bodies have standard features.

Chlamydial Infection and Inflammation
Inflammation is part of the innate immune response and the body’s response to injury or
invader. It initiates suddenly when a pathogen or other insult is detected by cell surface
receptors.25 Inflammation can be either local or systemic and acute or chronic. Inflammation at
the local level is often characterized by 4 main signs- pain, erythema, increased warmth, and
swelling at the site of infection or injury. There are also changes to vascular permeability and
expression of cell adhesion proteins, which can aid in the recruitment of infection-fighting white
blood cells, including neutrophils, lymphocytes, and monocytes.26 Systemic inflammation can
result in leukocytosis, an elevated number of circulating white blood cells, and it can also result
in fever. Local inflammation is primarily mediated by cytokines, while control of systemic
inflammation can be neuroendocrine-mediated.27 Acute inflammation is also part of the immune
response to pathogen, invader, or injury; however, chronic inflammation is typically not a part of
the initial immune response to a pathogen. Chronic inflammation occurs when the body
continues to demonstrate these inflammatory responses for an extended period of time, which
suggests that either the body’s system of inflammatory checks and balances is not maintained or
that there is a persistent infection that is initiating the inflammation.28
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The inflammatory process is typically regarded as part of the innate immune response
and begins with pattern recognition receptions (PRR), which recognize pathogen-associated
molecular patterns (PAMPs) and/or danger-associated molecular patterns (DAMPs). 28 In the
case of C. trachomatis infection, inflammation begins with detection of a PAMP by the toll like
receptors (TLRs) on host epithelial cells or on tissue-resident macrophages. Lipopolysaccharide
(LPS) is a component of the outer layer of the cell wall of Gram-negative bacteria that is
detected by TLR4 and is an example of a chlamydial PAMP.29 Chlamydiae have also been
recently demonstrated to produce peptidoglycan, another PAMP, which is detected by TLR2.30
Once cell surface or cytoplasmic TLRs bind to their target PAMP or DAMP, they activate a
complex series of

intracellular signaling events that result in the translocation of nuclear factor

kappa beta (NFκB). Once in the host cell nucleus, NFκB increases transcription of many genes
related to the inflammatory response, including those encoding inflammatory cytokines.31
Following activation of NFκB, macrophages release cytokines, such as tumor necrosis factor
(TNF), interleukin-1 beta (IL-1β), IL-6, and IL-8. These pro-inflammatory cytokines are
associated with the start of local inflammation. TNF and IL- 1β increase vascular permeability to
allow immune cells to reach the affected area and have also been shown to significantly increase
the expression of cell adhesion molecules (CAM), resulting in increased leukocyte adhesion,
activation, and migration into tissues25, 32, 33 These neutrophils then participate in the immune
response by phagocytosis. After the neutrophils have been recruited, IL-6 can also function to
recruit monocytes.34 Chlamydial infection has been observed to result in significantly increased
levels of IL-8 35, which is responsible for the recruitment of neutrophils to the site of the
chlamydial infection. It is important to point out that the influx of neutrophils is critical for
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controlling chlamydial infection.36 Neutrophils can also function to attract other types of immune
cells, so the neutrophils can phagosytize the bacteria, as well as call on other cells to help fight
off infection by phagocytosis or releasing cytokines.37 The production of these pro-inflammatory
cytokines is essential for resolution of infection, but an excessive response of these immune cells
may be the cause of the inflammation-related injuries that can cause long-term damage.

The Cholinergic Anti-Inflammatory Pathway
When PAMPs, DAMPs, or pro-inflammatory cytokines are released, they can bind to
neuronal PRR or cytokine receptors and stimulate vagus nerve fibers capable of sending
information towards the brain stem. Following this communication with the brain, efferent vagal
nerve impulses can then trigger norepinephrine (NE) release from nerve terminals in the spleen,
and perhaps in the mucosal tissues of the gastrointestinal tract and lungs. This NE then binds to
β-adrenergic receptor 2, which stimulates the expression of the choline acetyl-transferase
(ChAT) enzyme and promotes synthesis of acetylcholine (ACh) by a sub-set of CD4+ T cells.
This secreted ACh binds α7-nicotinic acetylcholine (α7nAChR) on nearby macrophages, and
stimulates these receptors, reducing the activity of NFκB, which corresponds with decreased
production of pro-inflammatory cytokines (Figure 2).38 Thus, activation of the cholinergic antiinflammatory pathway (CAP) is one of several regulatory pathways that function to reduce
inflammatory responses in peripheral tissues.39
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Figure 2. The Cholinergic Anti-Inflammatory Pathway. Upon recognition of PAMP or DAMP,
such as Lipopolysaccharide in the case of chlamydial infection, cytokines are released. These
cytokines signal to the brain using the afferent vagal nerve. The efferent vagal nerve signals to
the spleen to release norepinephrine, which binds to a β-adrenergic receptor. CD4+ T-cells are
stimulated to release acetylcholine, and ACh binds to a nAChR, stimulating an increase in
production of anti-inflammatory cytokines and decreasing the production of NFκB, which results
in a decrease of the production of pro-inflammatory cytokines.*93
Cytokines such as IL-10 and IL-4, antagonists for IL-1 receptors, and transforming
growth factor beta (TGF-β) also all participate in counteracting inflammation. TNF and IL-1β
also work as mediators of inflammation in the brain on top of their local influence.40, 41, 42 In
addition to these pathways, when the vagus nerve is activated, afferent sensory neurons signal to
the brain that inflammation is occurring.27, 28, 43 The vagus nerve, part of the Autonomic
Parasympathetic Nervous System, stimulates production of anti-inflammatory responses in the
hypothalamus, pituitary gland, and adrenal gland.44 The vagus nerve can function as a link
between the immune system and the brain. This mechanism, which is involved in modulating
immune response, is termed the “cholinergic anti-inflammatory pathway.”
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Vagal Nerve Involvement
The tenth cranial nerve, the vagus nerve, is the longest nerve in the human body, starting
at the brain and traveling down to a number of organ systems. It is involved in a multitude of
processes and functions, as it is the nerve with most complex and expansive distribution.45 It is
composed of mixed nerve fibers and is involved in both sensory and motor function.46 Recent
research has focused on the relationship between the vagus nerve and immune function.
Specifically, attention has been focused on the parasympathetic nervous system.27 In a 2002
review, Tracey outlined the role of vagus nerve stimulation and the inflammatory process,
termed “the inflammatory reflex.”47 In essence, the inflammatory reflex provides information
about the links between local inflammation and the central nervous system. Stimulation of the
immune system initiates processes, such as the release of cytokines and chemokines that allow
the peripheral tissues to communicate with the brain through the vagus nerve. Subsequently,
immune function can be regulated through a neural pathway.
Importantly for our study, it has been shown that the vagus nerve indirectly innervates the
genital tract. Gerendai and Halasz performed a small study that shows a connection between the
vagus nerve and ovarian function. Specifically, they found that ovarian regulation was affected
by interference with the physiology and function of the vagus nerve.48 Furthermore, there is
evidence that the vagal nerve branches extend to the uterus49 and can receive information from
the lower genital tract. Current research shows that the lung and gut, which are innervated more
directly by the vagus than the genital tract, demonstrate similar methods to regulate the mucosal
immunity process.26, 27 Thus, the inflammatory reflex described initially by Tracey may also
contribute to regulation of immune process initiated by sexually transmitted infections such as
chlamydial infection in the genital tract.
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Importance of Anti-Inflammatory Responses
The inflammatory reflex’s role is significant because it serves to regulate the body’s
immune response. With this regulation, the body attempts to protect itself from the detrimental
effects of inflammation as a function of the immune response. There is potential therapeutic
importance behind this phenomenon, because it may be a method that can be employed to
prevent the effects of conditions related to excess inflammation within the body.46, 50, 51 For
example, Pavlov et al. demonstrated that treatment with the alpha 7 nAChR agonist GTS-21
protects mice from the lethal effects of sepsis, a disease the lethal effects of which are partially
mediated by over-production of inflammatory cytokines and systemic inflammation. The authors
proposed that, as would be predicted by the CAP model illustrated in Figure 2, GTS-21 acts by
reducing inflammatory cytokine production much like ACh acts during CAP activation.52 These
experiments, and many others, illustrate how CAP function might be modulated to reduce the
severity of inflammatory diseases in humans. A 2017 review by Hoover summarizes recent
research developments about the CAP. 50 Recent data suggests that vagal nerve stimulation can
result in anti-inflammatory effects. Hoover also discussed the possibility that α7nAChRs may
provide a new mechanism that may be employed to approach treatment of conditions that can
cause damage as a result of excess inflammation.53 Specifically, it may be possible to repurpose
current therapies, such as Memantine, which will be further addressed in a subsequent section.
The idea behind this is that the manipulation of the innate α7nAChRs may aid in controlling
inflammation and, thus, it may prevent some of the down-stream effects of chlamydial infection
– many of which are elicited by chronic inflammation.50
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Acetylcholine and its Function
Acetylcholine (ACh) is a neurotransmitter of high importance in the body. It is found in
numerous places throughout the CNS, is involved in ganglion synaptic transmission in the
sympathetic and parasympathetic neurons, and is also a major component of postganglionic
efferent neurons. Acetylcholine is not limited to the nervous system, however. For example,
research published in 1982 indicates the acetylcholine is present in denervated skeletal muscles,
indicating the presence of ACh is peripheral tissues.54 Research has also shown that ACh is
present in the circulating blood of mammals, as well as the spleen.55 This information confirms
the possibility that ACh may have effects that have remained undiscovered, such as involvement
in immune function.

Synthesis. ACh is formed from acetyl coenzyme A (acetyl CoA) and choline. This reaction is
made possible by catalysis from choline acetyltransferase (ChAT) as well as carnitine
acetyltransferase (CarAT). A review analysis by Kawashima et al. in 2015 found that, in
different cell lines, ChAT but not CarAT activity corresponded with the amount of ACh found in
the cells. From this, they concluded that ChAT is responsible for the synthesis of ACh in
lymphocytes. These observations also indicate that ChAT levels can be used as an indirect
indicator of ACh production in various cell types. In fact, ChAT expression is a commonly used
experimental marker for ACh production.56, 57 Both non-neuronal cells, such as T cells, and
neurons produce ACh. This ACh then binds to receptors on non-neuronal cells, such as
endothelial cells, and immune cells such as macrophages.
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Receptors. ACh exerts its biologic effects by binding to two main types of receptors—
muscarinic, G-protein signal transduction receptors, and nicotinic, ion channel pore receptors.
Muscarinic receptors are associated with biological processes such as heart rate, smooth muscle
contraction, and neurotransmitter released, while nicotinic receptors are more closely related to
signaling and transmission. 43, 58 Non-neuronal ACh and the AChR (acetylcholine receptors)
have a number of functions in immune regulation. α7nAChRs have been of special interest in the
investigation into cholinergic regulation of immune processes.58, 59 Once activated, α7nAChRs
results in depolarization of the membrane of the immune cells and excitation due to a change in
ion permeability. Immune cells such as macrophages express the α7 subunit of the nicotinic
acetylcholine receptor. When ACh binds to an α7nAChR, it prevents the release of TNF, which
is secreted by macrophages in response to an immune threat.42 Thus, the inflammatory process is
attenuated. These findings indicate that acetylcholine is part of a specialized circuit involving the
efferent vagus nerve, because it is capable of taking advantage of α7 receptors for signaling and
decreasing pro-inflammatory cytokines.60 Importantly, Yamaguchi et al. showed that
acetylcholine, as well as other nicotinic acetylcholine receptor (nAChR) agonists, enhanced the
growth of Chlamydia pneumoniae infection in vitro; these findings indicate that nAChRs may
also act directly on developing Chlamydiae, in addition to their role in neurotransmission and
immunologic regulation.61
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Regulation of Mucosal Immunity by the CAP
Mucosal Immunity
Once an injury or infectious agent has surmounted the mechanical and chemical barriers
that are part of the natural defense system, another line of defense is employed to protect the
body from these insults. This line of defense is the innate immune system.25 Phagocytes are a
significant part of the innate immune response, and they function at the site of the invader or
insult. The word phagocyte translates as “a cell that eats,” which gives insight into its function.
Phagocytes engulf particles that are detected as foreign, such as pathogens or other types of small
cells and then travel to the lymph nodes.62 Innate immune cells, including macrophages,
neutrophils, and dendritic cells, demonstrate phagocytic activity. These cells also have Toll-like
receptors (TLRs). These TLRs can detect characteristics that are often associated with pathogens
and invaders, sometimes termed PAMPs. Following detection of a pathogen-associated
characteristic by their TLRs, these dendritic cells and macrophages can secrete cytokines and
chemokines, which allow for the recruitment of other immune cells. Activated dendritic cells can
then enter lymphoid tissues and activate pathogen-specific T-cells within the lymphoid system.
Following activation of the T-cells, they can either migrate to the site of the infection or stay in
the lymphoid system, where they can help activate other T-cells, as well as B-cells.25
The CAP is a significant part of the regulation of mucosal immunity. This regulation is
achieved by affecting the amount of inflammation, part of the innate immune response, at the site
of an invader or injury. The CAP begins with detection of an insult to the cell through
recognition of LPS or other pro-inflammatory cytokines with the help of PAMPs or DAMPs.
Ultimately, this process results in reduced inflammation overall. Since the genital tract is
innervated by the vagus nerve, albeit indirectly, it is possible that an infection in the genital tract
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could activate the CAP. Similar phenomena have been observed in the lung and digestive
mucosa.51

Lymphocytes
T cells are thought to have a significant regulatory effect on the CAP. One of the first
suggestions of T cell involvement occurred when Fuji et al.60 observed that a T cell activator,
phytohemagglutinin (PHA), corresponds to an increase in ACh. Specifically, they were able to
determine that PHA affects ChAT, but not CarAT, activity, suggestive that only the ChAT
enzyme corresponds with T cell involvement.61 The finding that T-cell involvement is correlated
with the presence of the enzyme ChAT is of importance, because it supports the use of
genetically engineered ChATgfp mice to investigate possible effects of chlamydial function on
immune response. Since infections result in activation of T-cells and T-cells correspond with the
production of acetylcholine, it may be possible to achieve better understanding of the immune
response as a result of chlamydial infection by further investigating how lymphocyte production
changes.

Activation
Once the dendritic cells and macrophages are activated following the detection of a
PAMP, such as LPS, T-cells are activated, which can result in ACh synthesis. This synthesized
ACh then acts to regulate immune processes. It does so by reducing the production of proinflammatory cytokines, such as TNF and interleukins. With the knowledge that ACh synthesis
is dependent on T-cells, there could be therapeutic potential to regulate the expression of ChAT
by blocking antigen presentation between CD4+ T cells and APCs. 57, 63 If the APCs are no
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longer able to present to the the T-cells, the inflammation would be reduced and initiation of
adaptive immune responses halted.

Strategies of Infection
One of the treatment challenges associated with urogenital chlamydial infection is that it
has a tendency towards recurrence.64 Persistence is characterized by the ability for the bacteria to
exist in a non-culturable state. During the persistent state, the hosts do not show signs of
infection, and it is often undetectable. It is also worth considering that many of the individuals
that do have a detectable C. trachomatis infection receive treatment but do not make lifestyle
changes, leading to a greater likelihood of reinfection. More recent studies have suggested that
IFN-ϒ treatment, as well as antibiotic treatment can lead to the aberrant state. 7, 65, 66 In addition,
iron deficiencies and other nutrient limitations may also lead to formation of AB.67, 68 These AB
may be allowing the chlamydial inclusions to remain in the human body, while avoiding
degradation. As discussed previously, this is thought to be a method of establishing long-term
infection in the host, because it allows the chlamydial cells to remain alive despite stressful
conditions. After the removal of these stressors, the AB can convert back to RB so that they can
then multiply or convert to the EB form and go on to infect additional cells.69

Current Treatment with Antibiotics
The Center for Disease Control (CDC)-recommended treatment guidelines suggest
Azithromycin or Doxycycline to treat chlamydial infection. However, alternative treatments
include Erythromycin, Levofloxacin, and Ofloxacin.70 Treatment challenges arise when an
individual has asymptomatic infection but is treated with a beta-lactam antibiotic for another
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reason, as this may help induce a persistent state of the bacteria.23 There are also numerous
studies focusing on the development of a vaccine to inoculate against C. trachomatis. Some
scientists believe that a vaccine may be an optimal management strategy due to the nature of
urogenital chlamydial infections, because C. trachomatis can employ unique strategies, such as
its genetic change capabilities, to evade the innate infection-fighting immune response and
treatment by antibiotics. 71, 72 Nonetheless, unless the disease is eradicated, there will still be
inflammation related sequelae if the inflammation deregulation process is not remedied. Current
studies, such as the one we are conducting, are looking more specifically at ways to manipulate
what we know about current immune response and chlamydial pathogenesis. A 2015 research
article by Yu et al. focuses on repurposing a current Alzheimer’s Disease treatment, Memantine,
to treat bacterial infections through manipulating the cholinergic anti-inflammatory pathway
using nAChR. They found that Memantine is capable of modulating both inflammatory and antiinflammatory pathways within the host. Combined with the use of appropriate antibiotics, it may
be an effective therapy to treat sexually transmitted diseases or other bacterial infections.
However, it is important to note that Memantine alone would not be a sufficient treatment for
chlamydial infection, as the potential utility of Memantine is focused on reducing inflammation
and disrupting the inflammatory response. 72, 73 Rather, it offers a possible mechanism of
treatment for the potential side effects of chlamydial infection, such as inflammation-related
injuries.73

Challenges
Despite these future possibilities and advancements, we continue to strive to develop
alternative infection treatment and management strategies. One commonly faced issue in
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healthcare is the increased risk of antibiotic-resistant bacteria due to overprescribing of
antibiotics. Even with multiple effective pharmaceutical treatments for chlamydial infections,
there can still be significant negative effects, both medically and economically. It is in our best
interest to continue seeking treatment options that are more effective and to continue learning
about host-bacteria interaction. Thus, we hypothesized that urogenital C. trachomatis infection
results in increased levels of ACh within the host cells and that the ACh enhances urogenital
chlamydial infection.
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CHAPTER 2
MATERIALS AND METHODS
Overview
To determine whether chlamydia infection regulates the CAP, we examined production
of ChAT in vaginally infected ChATgfp transgenic mice. These mice contain a transgene
composed of the ChAT-promoter driven expression of a green fluorescent protein (GFP) gene.
Since the ChAT enzyme is required for ACh production, ChAT promoter activity is a commonly
used experimental marker to determine if cells are producing ACh.56, 63 Thus, we determined
how many host genital tract cells in this ChATgfp mouse line were producing ACh by staining
tissue sections with an anti-GFP antibody.57 In addition, we determined if the ChAT-expressing
cells are at the same tissue location as the chlamydia inclusion-containing cells using antichlamydia antibody staining. The comparison between the number of ChAT-expressing cells and
cells containing chlamydial inclusions was determined using immunohistochemistry (IHC) of
mouse tissues. The mice were infected with C. muridarum Weiss strain (a Chlamydia species
that infects mice) and sacrificed at days 3, 9, 15, and 21 post-infection.75, 76 Tissues from the
cervix, uterine horn, and ovaries were harvested for the immunohistochemistry assays.
Chlamydial titer assays were also performed as a positive control to confirm that chlamydiainfected mice were shedding chlamydiae. The numbers of ChAT-GFP producing cells were
counted via a microscope with a 63x oil-immersion objective lens, equating to 630x
magnification. For each slide, an average of twelve counts from three tissue sections was
determined, using two non-consecutive sections. Data were averaged and the standard error of
the mean values calculated and compared using an independent T test.
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Murine Modeling
A review by De Clerq et al.77 explores animal modeling in chlamydial research. The
similarity between human urogenital chlamydial infections and murine modeling systems is
dependent on the strain of mouse and the chlamydial species used. For example, C. trachomatis
infection is typically less severe in most non-human animal models than in humans. It does not
typically ascend up the genital tract, and it often resolves on its own.74, 77 However, C.
muridarum cervicovaginal infection in mice ascends to the upper genital tract from the cervical
tissues, as observed with C. trachomatis in humans. C. muridarum genital tract infection also
causes hydro- and pyo-salpinyx and reproductive complications similar to those observed in C.
trachomatis infected humans.17 For these reasons, C. muridarum is the most widely used animal
model for chlamydial genital tract infection. Therefore, we chose the C. muridarum
cervicovaginal infection model to use in our studies. Notably, murine genital infection is also
affected by the stage of the estrous cycle at the time of infection. Likewise, the estrogen and
progesterone levels within the organism being studied affect C. trachomatis infection
significantly.75 Thus, the estrous cycles of all mice used in these studies were synchronized by
hormone treatment prior to infection, as described below.

Animal Handling and Infections
ChATBAC-eGFP mice (MGI ref ID J:114554; PubMed ID:1694043) from Jackson
Laboratories were used for all experiments.76 Male and female homozygous founder mice were
obtained from Jackson Laboratories and used to establish a breeding colony in the Quillen
College of Medicine DLAR. All mice were provided food and water ad libitum and kept on a
standard 12-hour light/dark cycle. After 1-week acclimation period, 9-week-old mice were
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subcutaneously injected with 2.5 mg Depo-Provera (Greenstone LLC, Peapack, NJ). Mice were
vaginally infected using a micropipette at 10 weeks of age with 106 inclusion-forming units
(IFU) of C. muridarum Weiss strain in 2SPG on day 0, represented by the star in Figure 1. C.
muridarum Weiss strain was obtained from Kyle Ramsey (Midwestern University). Mockinfected animals were included in each experiment and received 10µl of 2SPG alone on the
infection day. A total of 6 mock and 5 infected animals from at least 2 separate infection
experiments were analyzed at each time interval described in these studies. Mice were sacrificed
at days 3, 9, 15, or 21 post-infection by cervical dislocation. To determine pathogen shedding,
vaginal swabbing and titers were performed every 3 days, as described by Phillips-Campbell et
al.77 (Figure 3) All animal experiments in this study were conducted in strict accordance with the
National Institutes of Health “Guide for the Care and Use of Laboratory Animals.” The
University Committee on Animal Care at East Tennessee State University approved the animal
protocol under the guidelines of the Association for Assessment and Accreditation of Laboratory
Animal Care, US Department of Agriculture, and in compliance with the Public Health Service
Policy on Human Care and Use of Laboratory Animals.

Figure 3. Experimental timeline. Star at Day 0 indicates day of infection. Titers were taken every
three days. Mice were sacrificed on days 3, 9, 15, and 21 post-infection.
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Tissue Collection, Fixation, and Embedding
Genital tract tissues were removed and immersed in 10% unbuffered formalin made from
10ml formaldehyde 37-40% (Fisher Scientific, Waltham, MA) and 90ml distilled H2O for 48-72
hours. Tissues were then transferred to 70% EtOH and stored at 4°C for 24-72 hours until they
were embedded in paraffin. Paraffin blocks were stored at ~20-25°C with a desiccant for a period
of up to two years until being cut. They were cut into 5µm slices using a microtome and placed
on positively charged microscope slides (Fisherbrand Superfrost Plus, catalog #12-550-15, lot
#010515-9). The slides were allowed to dry overnight. Then, IHC was started the next day or
they were stored for future use (at room temperature). ABC immunohistochemistry was used to
stain for ChAT-producing cells within the tissue using anti-GFP antibody-ChIP Grade (ab290,
lots GR278073-1 and GR196874-1, rabbit polyclonal, Abcam, Cambridge, UK).
In addition to anti-GFP staining to look at the presence of ChAT within the tissues,
staining using an antibody to C. trachomatis was performed using the same method as the antiGFP staining. The only differences were the antibody used at the primary antibody stage of
immunostaining (Rb pAB to C. trachomatis, catalog ab31131, lot GR235293-2) and the length
of time that the VIP substrate was on the tissues (20 minutes). Slides were analyzed at 40x
magnification for a total of 400x magnification. The number of inclusion-containing cells was
not quantified. Instead, they were analyzed qualitatively to look for the presence or absence of
chlamydial inclusions.
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Immunohistochemistry
Rehydration
Microscope slides with tissues sections were placed into a glass slide rack and placed in
60°C oven for 30 minutes to melt paraffin and desiccate the samples. After 30 minutes, the slides
were removed in the slide rack, and the slide rack was placed on the bench surface for
approximately 30 minutes to allow the slides to cool to room temperature. After the slides were
brought to room temperature, they were rehydrated. The slides were rehydrated with xylene for
two 5-minute increments, 100% EtOH for two 2-minute increments, 95% EtOH for two 2minute increments, 75% EtOH for one 2-minute increment, 50% EtOH for one 2-minute
increment, distilled H2O for two 5-minute increments, and 0.1M OBS for one 5-minute
increment.

Antigen Retrieval
Slides were then placed in Tissue-Tek slide holder. The container was then filled with
Antigen Retrieval Solution (Appendix A) and microwaved at full power for 3.5 minutes and then
using the defrost setting for 6 minutes. The slides in the Tissue-Tek slide holder were removed
and placed on bench to allow them to cool to room temperature (45 minutes). After cooling to
room temperature, the slides were washed in distilled H2O three times for 5 minutes per wash.
Following the dH2O wash, the slides either started in the immunostaining protocol or were stored
in IHC PBS for 24-72 hours at room temperature until immunostaining.
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Immunostaining
Slides were washed in IHC PBS for four washes, each lasting 5 minutes. Then they were
washed once in 0.5% BSA (Appendix A) for 10 minutes, once in 1% H2O2 for 15 minutes, four
times in IHC PBS for 5 minutes each, and finally, once in 0.5% BSA again for 10 minutes.
Slides were removed one at a time, and the area surrounding the tissue was dried using a
Kimwipe. ImmEdge hydrophobic barrier pens (Vector Labs, Burlingame, CA, catalog # H4000)
were used to draw water barrier circle around each section of tissue on the slide. The barriers
were given one minute to dry before slides were placed into a humidity box and covered with
blocking buffer (Appendix A). After 2 hours of incubation at room temperature, the blocking
buffer was poured off of each slide and replaced with primary antibody solution (Appendix A).
The slides were then allowed to incubate overnight (at least 2.5 hours but not more than 36
hours) at room temperature.
After primary antibody staining, slides were washed four times in IHC PBS at 5
minutes/wash, and then, washed with 0.5% BSA once time for ten minutes. Slides were removed
from BSA and gently dried using Kimwipes, carefully avoiding the tissue. Biotinylated
secondary antibody solution (Appendix A) was placed on the tissue sections and allowed to
incubate at room temperature for two hours. Slides were rinsed in IHC PBS, washed four times
in IHC PBS for 5-minutes/wash and, finally, subjected to one 10-minute wash in 0.5% BSA. The
tissues were again removed from the slide holder and gently dried, before being covered with
ABC reagent and incubated for 1.5 hours. The ABC reagent was poured off of each slide before
the slides were washed in TBS four times at 5-minutes/wash. Slides were removed from slide
holder, gently dried, and then placed on a light-colored background. The VIP Substrate (Vector
Laboratories, Burlingame, CA, catalog SK-4600) solution was applied to each tissue section and
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allowed to develop for 2 minutes for ChATgfp staining or 20 minutes for chlamydial staining.
Slides were rinsed in dH2O and then washed for two 2-minute periods. Then, slides were
counterstained using Methyl Green (Vector Laboratories, Burlingame, CA, catalog # H-3402) for
2 minutes at room temperature (~23°C). Slides were rinsed in ddH2O and then washed twice for
2-minutes/wash in ddH2O Slides were dehydrated using the opposite order of the rehydration
protocol, starting at 50% EtOH, up to xylene. Following the last soak in xylene, the tissues
remained in the last xylene-staining dish until being removed one by one for coverslip
placement. Cytoseal 60 (catalog # 327734, lot #8310-4) was used to mount coverslips over the
tissue sections. After applying coverslips, the slides were allowed to lie flat at room temperature
until they were viewed under the microscope. In the event of water under the coverslip, the slides
were soaked in xylene for no more than 30 minutes so that the coverslip came off without
disturbing the tissue, and a new coverslip was mounted on the slide.79, 80, 81

Data Collection and Analysis
Data was collected from IHC tissues using 630x magnification oil immersion microscopy
to count the number of ChAT-producing cells as described previously.74, 75 Counts were taken
from at least 2 non-consecutive tissue slices per slide for each tissue. Slides contained
approximately 4 tissue sections each. Two slices or sections of tissue were counted per slide, and
there were twelve fields within each slice/section. Microscopic fields were non-consecutive.
Tissue counting started at the top left of the tissue and moved down and to the right in the
progressive fields. Every effort was made to ensure that fields did not overlap and that fields
were not all directly beside each other. Averages were determined for each tissue section; the
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averages were combined for each tissue type at each time point.82, 83 Independent T-test analysis
was used to determine significance (p<0.05), and standard error was calculated.
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CHAPTER 3
RESULTS
As the most common bacterial sexually transmitted infection in the world, Chlamydia
imposes significant financial burdens and can impose long-term consequences on infected
individuals that are not treated in a timely manner. Chlamydial infection presents unique
treatment and management challenges due to its ability to manipulate host cells to make a more
favorable intracecllular environment for survival and proliferation. Thus, it often goes
undetected. At this point, current treatment methodologies can be effective, but are not optimal
due to the ability of the organism to persist despite stressors. Additionally, antibiotic treatment is
associated with financial burden and possible contraindiations.
To better understand the pathogenicity mechansims behind infection with C. trachomatis,
we would ultimately like to understand how the organism interacts with the host’s immune
response. So far, a majority of the work investigating CAP activity and its effects on disease
have been limited to study of non-infectious disease processes, such as cancer87 and autoimmune
conditions.89, 90 In these studies, the non-infectious disease often benefits from nAChR
stimulation, which results in reduced inflammation. However, in infectious disease, the
significance of pro-inflammatory cholinergic responses is not as clear. Previous studies show
that it is possible for CAP activation to protect the infected host, as evidenced by reduced
mortality in sepsis and viral myocarditis with CAP stimulation.85, 91 Nonetheless, it is also
possible for CAP activation to be detrimental to the host, as demonstrated by the increased
mortality observed in Escherichia coli infected nAChR knockout mice that cannot activate the
CAP due to the absence of α7nAChR.87 In addition, the use of an α7nAChR agonist, such as
nicotine, to prevent initiation of the CAP has been found to increase the amount of inflammation
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in Staphylococcus pneumoniae infected mice, and increased bacterial load was observed.92 These
findings suggest that, in some ways, the CAP may aid pathogenicity, because it can reduce the
body’s innate immune response to infection. This raises the possibility that some organisms may
specifically activate the CAP by inducing host cellular ACh synthesis in order to evade host
responses and help establish infection. Based on this knowledge of CAP activity, we
hypothesized that C. muridarum-infection causes an increase in ACh production within genital
tract tissues. To begin to test this hypothesis, IHC using anti-GFP antibody was performed on
tissues extracted from ChAT-eGFP mice that were sacrificed on days 3, 9, 15, or 21 from the
time of inoculation with C. muridarum, allowing for the identification and enumeration of the
number of cells producing ChAT. An increase in the number of ChAT-expressing cells in C.
muridarum-infected genital tissue compared to that in mock-infected mice would suggest that
chlamydial infection does result in an increase of ACh, which would be consistent with our
hypothesis.
To start, we C. muridarum infected or mock-infected female ChATBAC-eGFP mice as
described in the methods. Neither C. muridarum nor mock-infected showed any sign of distress
and all mice survived for the duration experiment until the sacrifice date (Figure 3). There was
no detectable chlamydial shedding in mock-infected mice. All chlamydial-infected mice shed
infectious C. muridarum EB, with maximum shedding observed at day 3 post-infection (data not
shown).
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Effect of Chlamydial Infection on ChAT Production within Cervical Tissue
Table 1 shows the average number of ChAT positive cells/microscopic field obtained
from cervical tissue isolated from C. muridarum- and mock-infected mice. At all three time
points, we observed an increase in the average number of ChAT-producing cells in infected
tissues as compared to genital tissues from mock-infected mice. Statistically, the number of
ChAT-producing cells was significantly increased on days 3 and 15, and 21post-infection (pi).
On day 21pi, there was a large difference in the averages of the mock and infected tissues (Table
1), but there was also a large degree of variability between different samples. (Figure 4). These
findings suggest that C. muridarum increases ACh production in the cervix within infected mice.
This is inferred from the increased number of cells that produce ChAT, which, as stated
previously, is necessary for ACh production and is a commonly used experimental marker for
ACh synthesis.
Table 1. Summary of counts of ChAT-gfp producing cells within cervical tissue samples
harvested at time points 3, 15, and 21 days post-infection. p<0.05

* Significant at the 0.05 probability level.
** Significant at the 0.01 probability level.
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Figure 4. ChATgfp Cervical Tissue Data. A. Representative images from each time point- days 3,
15, and 21 in both mock- and Cm-infected groups. Yellow arrows indicate ChAT positive cells.
B. Comparison of average counts for mock vs. infected tissues. * indicate those values that are
significantly different at P=0.05 or P=0.01. Images taken with 630x maginification.
Effect of Chlamydial Infection on ChAT Production within Uterine Horn Tissue
Table 2 shows the average number of ChAT positive cells/microscopic field obtained
from uterine horn tissue isolated from C. muridarum- and mock-infected mice. In the uterine
horn, the number of ChAT cells in infected tissues showed a statistically significant increase
from the mock tissues on days 3 and 9 (Table 2). Again, infection appeared to increase the
number of ChAT positive cells at all time points (Figure 5). Since chlamydial infection ascends
up the genital tract, it is reasonable to expect that the amount of change between mock and
infected averages may increase as the uterine horn tissues become more heavily infected at later
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times post-infection. However, this is not reflected in the collected data. Further testing with
more samples would help support or refute this possibility.
Table 2. Summary of counts of ChAT-gfp producing cells within uterine horn tissue samples
harvested at time points 3, 9, 15, and 21 days post-infection. p<0.05

* Significant at the 0.05 probability level.
** Significant at the 0.01 probability level.

Figure 5. ChATgfp Uterine Horn Tissue Data. A. Representative images from each time pointdays 3, 9, 15, and 21 in both mock- and Cm-infected groups. Yellow arrows indicate ChAT
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positive cells. B. Comparison of average counts for mock vs. infected tissues. * indicate those
values that are significantly different at P=0.05. Images taken with 630x magnification.
Effect of Chlamydial Infection on ChAT Production within Ovarian Tissue
Finally, Table 3 shows the average number of ChAT positive cells/microscopic field
obtained from ovarian tissue isolated from C. muridarum- and mock-infected mice. Ovaries had
significantly more ChAT cells in the infected tissue samples as compared to the mock tissue
samples on days 3, 15, and 21 pi (Table 2). The largest amount of variation between mock and
infected tissues samples at each time point was observed in ovarian tissues. As mentioned
previously, if considered in conjunction with the ascending nature of urogenital chlamydial
infection, there is the possibility of a correlation between later time points post-infection,
ascension of infection, and the effect on ChAT production.
Table 3. Summary of counts of ChAT-gfp producing cells within ovarian tissue samples
harvested at time points 3, 9, 15, and 21 days post-infection. p<0.05

* Significant at the 0.05 probability level.
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Figure 6. ChATgfp Ovarian Tissue Data. A. Representative images from each time point- days 3,
9, 15, and 21 in both mock- and Cm-infected groups. Yellow arrows indicate ChAT positive
cells. B. Comparison of average counts for mock vs. infected tissues. * indicate those values that
are significantly different at P=0.05. Images taken with 630x magnification.
Anti-Chlamydia Staining
As an additional control that genital tissues were infected, IHC staining for C. muridarum
inclusions was also performed (Figure 7). There were no quantitative methods applied to these
tissues following immunohistochemistry. Instead, the tissues were reviewed qualitatively to look
for the presence of chlamydial inclusions. In all tissue types and time-points, there were C.
muridarum-containing cells in the Cm-infected tissues, and there were no C.muridarumcontaining cells detected within the mock-infected group, which would have suggested a false
positive result.
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Mock

Infected

Figure 7. Representative anti-Cm staining. Cervical tissue samples taken from a mock-infected
and Cm-infected mouse sacrificed at day 3pi. Yellow arrows indicate C. muridarum positive
cells.
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CHAPTER 4
DISCUSSION
Implications for Chlamydial Pathogenesis
The deactivation of an inflammation management mechanism, such as the CAP, could
result in deleterious effects and increase the likelihood of the host suffering inflammation-related
injury. Our findings suggest that this could be a potential method of pathogenesis for C.
trachomatis. When chlamydial infection causes the production of acetylcholine to increase, the
CAP will be activated. This would cause an increase in anti-inflammatory cytokines, as well as a
decrease in pro-inflammatory cytokines. The decreased in pro-inflammatory cytokines would
then diminish leukocyte attraction to the infection site and subsequent activation. When the the
recruitment of immune cells is reduced, the likelihood that the bacterium is phagocytized or
killed by the host’s immune response is decreased. Furthermore, if the T-cells and B-cells are not
recruited or recruited only minimally, this would prevent the host from developing or cause
underdevelopment of adaptive immunity to C. trachomatis. Since C. trachomatis evades much of
the innate immune response, it would be expected to reproduce rapidly. If this happens, there is
such a great amount of bacteria present that, if the CAP is turned off, the body cannot fight off
the infection alone. This may result in more severe disease, more rapid genital tract ascension, or
increased transmission to new hosts.
Interestingly, C. trachomatis and other members of the Chlamydiae family have a unique
relationship with neutrophils. As mentioned previously, neutrophils are some of the first
responders from the immune system in response to an infection. They are able to phagocytize the
infectious agents, and this is done by ingesting the organism and then initiating apoptosis shortly
thereafter. However, C. trachomatis is actually able to delay the apoptosis by exposing the

43

neutrophils to pro-inflammatory cytokines.93, 94 Since neutrophils express pro-inflammatory
activity and C. trachomatis can postpone apoptosis, the result is increased inflammation at the
site of the infection due the the combined activity of the neutrophils. 93 The effect of C.
trachomatis infection on neutrophils is one of the mechanisms through which chlamydial
infection can cause lasting damage to the tissues due to excessive inflammatory response.
For an individual that is infected with C. trachomatis, there is an increased likelihood of
developing other STIs.2, 9 The pathogenic mechanism of evading the immune response may be
one of the reasons behind this. For example, studies have shown that individuals with Chlamydia
are at increased risk of contracting HIV if exposed.10 Though the mechanisms by which
chlamydial infection promotes other STI is unknown, it is possible that chlamydial infectioninduced down-regulation of the immune response by activation of the CAP could increase host
susceptibility to other genital tract pathogens.
Conversely, if the CAP was downregulated or prevented from initiating, there would be
an increased amount of pro-inflammatory cytokines present and a decrease in the release of antiinflammatory cytokines. With the increase of the pro-inflammatory cytokines comes the risk of
an inflammatory response that is so strong that it results in inflammation-related injuries, such as
pelvic inflammatory disease and urethritis. However, if we understand that the CAP can reduce
inflammation and that the CAP can be initiated through vagal stimulation, there is potential
application for treatment of inflammation-related conditions by vagal stimulation. So, in the case
of a hyper-response of the immune system, it may be possible to reduce inflammation and tissue
damage after an inflammatory stimulus. In chlamydial infection, increased activation of the CAP
may have utility in treating young females that still wish to reproduce, especially if they are
already at higher risk of inflammatory conditions, such as PID.
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Implications for Treating the Inflammatory Damage Caused by Chlamydial Infection
With increasing concern about antibiotic-resistant bacteria, there is more and more
pressure to develop alternative treatment methods for bacterial infections. Fortunately, C.
trachomatis poses less risk of developing antibiotic resistance.81 However, there is an increased
risk of individuals infected with Chlamydia contracting other STIs, so chlamydia-infected
individuals may actually have concurrent infections with other bacterial species that cause STIs.
When antibiotics are administered to treat the chlamydial infection, the other organism
responsible for a STI, such as Neisseria gonorrhoeae, may develop this antibiotic resistance.
Specifically, there has been a decline in susceptibility of N. gonorrhoeae to Azithromycin, which
the CDC recommends as part of a dual therapy.86 However, N. gonorrhoeae has been proven to
rapidly evolve, especially in terms of antibiotic resistance. Therefore, reducing antibiotic usage
by combining antibiotics with immunomodulators to treat STIs could be beneficial.
Understanding the effects of chlamydial infection on the inflammatory response can
contribute to potential therapeutic strategy to prevent and treat inflammation-related injury. In
the case of chlamydial infection, this may allow for significant decrease in the number of lasting
complications from urogenital chlamydial infection, such as chronic pelvic pain, PID, and
infertility. Understanding the infection’s potential effects on the host’s immune defenses, such as
down regulation of pro-inflammatory processes and cytokine release, may also help develop
another approach to treat other infectious diseases that similarly manipulate host physiological
function to proliferate. If the inflammatory process can be manipulated to allow the body to fight
off infection as needed but to not have so much inflammation that there are lasting consequences,
it may allow for a revolutionary new method of treatment. This would require a delicate balance
between activation and down regulation of CAP activity. For example, there is potential for
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supplementation to antiviral or antibiotic therapies, such as in the case of infection. It will be
particularly advantageous if these concepts can be applied using previously approved therapeutic
agents so that new treatments can be developed more effectively, such as Memantine, as
previously discussed.
Chlamydial infection poses a unique challenge since it is capable of affecting immune
response in two extreme manners-- either by attenuating the inflammatory response or overactivating it. There are already a number of studies and investigators that are researching
potential treatments for infections that affect the host’s immune response and can harm the host
through dysregulation of the inflammatory process. Our findings suggest that urogenital
chlamydial infection does increase the production of acetylcholine, part of the cholinergic antiinflammatory pathway, so it is possible that managing the inflammatory response could be
beneficial in the treatment of chlamydial infections. Treatment by immunomodulation through
administration of pro-inflammatory or anti-inflammatory cytokines, stimulation of the CAP,
altering chemokine levels, and affecting the activation of T-cells, are all possible methods to
control inflammation.84 In the case of infected individuals with a weakened immune response, it
may be helpful to down-regulate the CAP. There is also therapeutic potential in dampening the
inflammatory response, which may be achieved through stimulation of the CAP, administration
of the anti-inflammatory cytokines, or activating T-cells to increase ACh production.
Therapeutically decreasing the inflammatory response could prove helpful in managing
conditions such as sepsis. Nonetheless, immunomodulation does pose significant challenges,
because global effects on inflammation may result in unintended consequences. Specifically,
dampening the immune response could increase susceptibility to infection. In the case of
preventing the activation of the CAP, there is risk that an inflammatory process may be robust
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enough to cause inflammation-related injury. Thus, for many immunomodulation-based
therapies to be effective and appropriately safe, further research is necessary to improve
specificity. If immunomodulation proves to be an effective treatment strategy, it may be used
independently or with the use of antibiotic and antiviral therapies to manage infection and reduce
the likelihood of inflammation-related injuries.

Limitations of the Study
Sample Size
The primary limitation of the study pertains to sample size. The study will benefit from
having more animals for each group—mock versus infected—at each time point. Increasing the
number of animals at each time point will allow us to better account for variations in technique
and to pinpoint outlying data. This is consistent with the data presented in Figures 4, 5, and 6.
Though increased ChAT + cells are observed at days 3, 15 and 21 post-infection (pi) for cervical
tissues and all four time intervals in uterine horn and ovarian tissues, the increase is only
statistically significant in cervical tissue at days 3, 15, and 21pi, uterine horn tissue at days 3 and
9 pi, and ovarian tissue at days 3, 15, and 21pi . It seems likely, therefore, that analysis of
samples from a greater number of mice would reduce the observed variability and demonstrate
significant differences at a greater number of sampling times for each tissue. Furthermore, due to
the nature of IHC experiments, especially the amount of labor required for each slide, analyzing
more samples would be beneficial. Ideally, another technique can be adapted that will allow for
larger sample sizes. There is increased likelihood in error due to the number of IHC experiments
performed, as there may be unknown variations in technique and conditions despite the effort
devoted to uniformity in each IHC experiment repeat. Currently, consideration is being given to

47

enumerating ChAT positive cells by intracellular anti-GFP staining followed by flow cytometry.
Ultimately, though the data set needs to be expanded, the observation of a significant increase in
Chat + cells in infected animals versus uninfected controls in the cervix on days 3, 15, and 21pi,
the uterine horn on days 3 and 9pi, and ovary on days 3, 15 and 21pi provides compelling
support for the hypothesis and for future studies. Though lower in number than in C. muridarum
infected tissues, ChATgfp-producing cells were detected in mock tissues. Since acetylcholine is a
part of the innate immune response and is expressed in non-neuronal cells, it is not wholly
unexpected for some ChAT to be detected in the tissues in the absence of infection. However, as
mentioned above, an increased number of repetitions, as well as confirmatory assays will be
helpful in ruling out whether this may be due to experimental error.

Specificity
IHC was used to detect expression of ChAT, which is an enzyme involved in the
production of ACh. Methods to test specifically for the presence of ACh, such as ELISA or Mass
Spectrometry, will confirm that there is a positive correlation between the expression of ChAT
and increased presence of ACh. To further investigate the application of current findings, it will
also be beneficial to do α7nAChR inhibitor studies that investigate how a change in the
availability and/or activity of ACh receptors affects the chlamydial infection. If α7nAChR
inhibitors or agonists were administered to chlamydia-infected mice, the CAP would not be
initiated by infection, because the ACh produced would not be able to bind to its receptors,
which is the initiating step for decreased inflammatory cytokine production (Figure 2). In this
case, the inflammatory response would lose a mechanism of modulation, so it would be expected
that there might be an increased risk of inflammation-related injury during or after infection.
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Despite years of investigation, there is still a great deal of information yet to be
discovered about chlamydial infections and pathogenesis. Since C. trachomatis operates as an
obligate intracellular parasite, it presents unique experimental challenges, but advancements in
genetic analysis are providing novel insight about how the organism operates and potential
methods for management and treatment.
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APPENDICES
APPENDIX A
IHC Reagent Recipes
IHC PBS (0.1 M PBS, pH 7.3)
Na2HPO4 (FW=141.96)

29.6 g

KH2PO4 (FW=136.09)

8.6 g

NaCl

14.4 g

- For 0.1 M: Adjust pH by adding drops of 1.0 or 5.0 N NaOH. Total volume should be 2L.
- For 1.0 M: Adjust pH by adding ~100mL of 5 NaOH. Autoclave 20 min, store at RT. Total
volume should be 2L. Use heat if it isn’t going into solution. Then leave to cool to RT before
adjusting pH). Autoclave to sterilize. (Liquid 20-minute cycle)

0.5% BSA Solution
BSA

5.0 g

Triton-X100

4.0 mL

Add BSA to IHC PBS in beaker and stir until dissolved. Add Triton-X100 and stir until
dissolved. Total volume should be 1L.

1.0% BSA Solution
BSA

1.0 g

Triton-X100

400 µL
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Add BSA to IHC PBS in beaker and stir until dissolved. Add Triton-X100 and stir until
dissolved. Total volume should be 100 mL.

Antigen Retrieval Solution
dH2O

300mL

900mL

1.5 L

Sodium Citrate

0.882 g

2.646g

4.41g

Adjust pH to 7 or slightly lower by adding drops of 1 N HCl. Filter Sterilize.

IHC TBS
Tris-HCl

6.35 g

12.7 g

Tris Base

1.18 g

2.36 g

NaCl

8.77 g

17.54 g

dH2O

1L

2L

Adjust pH to 7.5 using NaOH or HCl. Autoclave or filter sterilize.

1.0% H2O2 Solution
2 mL of 30% H2O2+ 58 mL IHC PBS = 60 mL total volume. H2O2 is stored at 4°C.
For 3 times the amount: 6 mL 30% H2O2 + 174 mL IHC PBS = 180 mL total volume.
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APPENDIX B
Data Tables

Tissue Sample
15A
16A
1A
17A
18 A
9A

Cervical
Mock or Infected
Time
Mock
Day 3
Mock
Day 3
Mock
Day 3
Infected
Day 3
Infected
Day 3
Infected
Day 3

Average
Mouse Study
0.059523809
Chat 3
0.0125
Chat 3
0.125
Chat 1
2.530208333
Chat 3
2.46875
Chat 3
1.28125
Chat 1

19A
20A
5A
21A
22A
6A
11A

Mock
Mock
Mock
Infected
Infected
Infected
Infected

Day 15
Day 15
Day 15
Day 15
Day 15
Day 15
Day 15

0.125
0.186111111
0.75
2.898148148
4.927083333
7.8
7.75

Chat 3
Chat 3
Chat 1
Chat 3
Chat 3
Chat 1
Chat 1

23A
24A
7A
25A
8A
12A
42A

Mock
Mock
Mock
Infected
Infected
Infected
Infected

Day 21
Day 21
Day 21
Day 21
Day 21
Day 21
Day 21

0.083333334
1.597222222
0.0625
1.833333334
3.645833333
5.916666667
7.930555556

Chat 3
Chat 3
Chat 1
Chat 3
Chat 1
Chat 1
Chat 4

Table 4. Averages for Each Cervical Tissue Sample. Average number of ChAT-containing
inclusions observed in cervical tissue at each time point, including mouse study and whether the
animal was mock-infected or infected with C. muridarum.
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Uterine Horn
Tissue Sample Mock or Infected Time
Average
15B
Mock
Day 3
0
16B
Mock
Day 3
0.013888889
1B
Mock
Day 3
0.375
2B
Mock
Day 3
0.125
17B
Infected
Day 3
0.833333333
18B
Infected
Day 3
0.516666667
9B
Infected
Day 3
0.708333333

Mouse Study
Chat 3
Chat 3
Chat 1
Chat 1
Chat 3
Chat 3
Chat 1

1B
2B
3B
4B
5B
6B
10B

Mock
Mock
Mock
Infected
Infected
Infected
Infected

Day 9
Day 9
Day 9
Day 9
Day 9
Day 9
Day 9

0.294270833
0.1875
0.302083333
0.916666667
0.479166667
1
1.041666667

Chat 2
Chat 2
Chat 1 & 2
Chat 2
Chat 2
Chat 2
Chat 1

19B
20B
5B
21B
22B
6B
11B

Mock
Mock
Mock
Infected
Infected
Infected
Infected

Day 15
Day 15
Day 15
Day 15
Day 15
Day 15
Day 15

0.066666667
0.166666667
0.541666667
2.541666667
1.916666667
0.666666667
0.291666667

Chat 3
Chat 3
Chat 1
Chat 3
Chat 3
Chat 1
Chat 1

23B
24B
7B
25B
8B
12B
42B

Mock
Mock
Mock
Infected
Infected
Infected
Infected

Day 21
Day 21
Day 21
Day 21
Day 21
Day 21
Day 21

0
0.104166667
0.291666667
2.6
1.083333333
1.166666667
5.611111111

Chat 3
Chat 3
Chat 1
Chat 3
Chat 1
Chat 1
Chat 4

Table 5. Averages for Each Uterine Horn Tissue Sample. Average number of ChAT-containing
inclusions observed in uterine horn tissue at each time point, including mouse study and whether
the animal was mock-infected or infected with C. muridarum.
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Tissue Sample
15C
16C
1C
17C
18C
2C
9C

Ovary
Mock or Infected
Time
Mock
Day 3
Mock
Day 3
Mock
Day 3
Infected
Day 3
Infected
Day 3
Infected
Day 3
Infected
Day 3

Average
Mouse Study
0
Chat 3
0
Chat 3
0
Chat 1
0.531565657
Chat 3
0.520833333
Chat 3
0.0625
Chat 1
0.273809524
Chat 1

1C
2C
3C
4C
5C
6C
10C

Mock
Mock
Mock
Infected
Infected
Infected
Infected

Day 9
Day 9
Day 9
Day 9
Day 9
Day 9
Day 9

0
0.041666667
0.310606061
5.095959596
0.604166667
0.666666667
6.633333333

Chat 2
Chat 2
Chat 1& 2
Chat 2
Chat 2
Chat 2
Chat 1

19C
20C
5C
21C
22C
6C
11C

Mock
Mock
Mock
Infected
Infected
Infected
Infected

Day 15
Day 15
Day 15
Day 15
Day 15
Day 15
Day 15

0.052083333
0
0.416666667
2.354166667
3.395833333
1.4375
1.020833333

Chat 3
Chat 3
Chat 1
Chat 3
Chat 3
Chat 1
Chat 1

23C
24C
7C
25C
8C
12C
42C

Mock
Mock
Mock
Infected
Infected
Infected
Infected

Day 21
Day 21
Day 21
Day 21
Day 21
Day 21
Day 21

0
0.041666667
0
3.645833333
2.458333333
1.875
6.222222222

Chat 3
Chat 3
Chat 1
Chat 3
Chat 1
Chat 1
Chat 4

Table 6. Averages for Each Ovarian Tissue Sample. Average number of ChAT-containing
inclusions observed in ovarian tissue at each time point, including mouse study and whether the
animal was mock-infected or infected with C. muridarum.
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